Akero Therapeutics

AKRO

Market cap $4.31B

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Akero Therapeutics, Inc. (NasdaqGS: AKRO) to Novo Nordisk A/S. Under the terms of the proposed transaction, shareholders of Akero will receive $54.00 per share in cash, and a non-transferable Contingent Value Right entitling its holder to receive a cash payment of $6.00 per share upon full U.S. regu.

NEW YORK, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Akero Therapeutics, Inc. (NASDAQ: AKRO ) related to its sale to Novo Nordisk A/S. Under the terms of the proposed transaction, Akero shareholders will receive $54.00 per share in cash, and a non-transferable contingent value right entitling its holder to receive a cash payment of $6.00 per share upon full U.S. regulatory approval of efruxifermin by June 30, 2031. Is it a fair deal?

Akero Therapeutics is being acquired by Novo Nordisk for up to $5.2 billion, driven by strong phase 2b results for EFX in F2/F3 pre-cirrhotic and compensated cirrhosis F4 MASH patients. Akero's EFX showed unprecedented reversal of cirrhosis and significant fibrosis improvement in the HARMONY and SYMMETRY studies, respectively, positioning it as a leader in FGF21 analogs. The acquisition includes $54 per share upfront as cash and a $6 per share CVR contingent on FDA approval for compensated cirrhosis due to MASH patients by 2031.

One of the best catalysts for sudden, sharp rise in the price of a stock is when the company behind it get acquired at a premium. Case in point: Akero Therapeutics (AKRO 16.33%), whose shares soared by more than 16% Thursday after it was revealed the biotech will have a new owner.

Major U.S. equities indexes pulled back Thursday after the S&P 500 and Nasdaq set fresh all-time highs. The Dow Jones Industrial Average, S&P 500, and Nasdaq all were lower at midday.

MILWAUKEE , Oct. 9, 2025 /PRNewswire/ -- The Ademi Firm is investigating Akero (NASDAQ: AKRO) for possible breaches of fiduciary duty and other violations of law in its transaction with Novo Nordisk. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.

Novo Nordisk said on Thursday it would buy U.S.-based Akero Therapeutics for up to $5.2 billion to add its promising experimental liver disease drug, in the first major deal by the Danish drugmaker's new CEO to boost growth.

Novo Nordisk A/S (NYSE:NVO) is down 1% to trade at $59 this morning, after news surfaced that the pharmaceutical concern has entered an agreement to purchase U.S.-based peer Akero Therapeutics Inc (NASDAQ:AKRO) for as much as $5.2 billion in cash.

Novo Nordisk A/S (NYSE:NVO) agreed on Thursday to acquire Akero Therapeutics, Inc. (NASDAQ:AKRO) focused on metabolic diseases.

Novo Nordisk said on Thursday it would acquire Akero Therapeutics for up to $5.2 billion in cash, marking a significant push into treatments for fatty liver disease as the Danish drugmaker seeks to broaden its pipeline beyond diabetes and obesity drugs.